TABLE 3.
Mean percentages of dendritic cell immunophenotypes in PB and BFa
| Surface antigen | % Cells with immunophenotype
|
|||
|---|---|---|---|---|
| Lipopeptide-injected subjects
|
Control blood (PB-NL) (n = 6) | |||
| Sample size | PB | BF | ||
| CD11c+ DCs | 22 | 50.2 (41.9-58.5) | 60.6 (50.7-70.7) | 61.0 (47.7-74.2) |
| CD83+ | 5 | 0.4 (−0.4-0.9) | 53.0 (5.4-100.6)b | 0.17 (−0.3-0.6) |
| CD86+ | 5 | 13.8 (−0.8-28.4) | 59.9 (32.01-87.6)b | 5.6 (−7.9-19.2) |
| CD80+ | 5 | 1.5 (−0.2-3.3) | 38.8 (14.5-63.1)b | 2.5 (−0.26-5.3) |
| DC-SIGNc | 6 | 5.0 (0.4-9.7) | 46.7 (19.5-73.8)c | 7.3 (0.4-14.2) |
| CD11c− DCs | 19 | 47.7 (39.1-56.2) | 38.1 (27.5-48.6) | 38.7 (22.7-54.6) |
| CD83+ | 5 | 0 | 1.9 (−1.8-5.7) | 0.3 (−0.5-1.1) |
| CD86+ | 5 | 12.6 (−2.7-27.9) | 9.3 (−5.9-24.6) | 2.9 (−1.9-7.6) |
| CD80+ | 5 | 15.1 (−6.0-36.2) | 1.7 (0.1-3.2) | 11.3 (−1.1-23.8) |
| DC-SIGNc | 6 | 3.2 (−1.2-7.8) | 12.2 (−9.5-33.9) | 6.8 (0.5-13.2) |
a
Numbers shown are mean percentages with 95% confidence intervals.
b
Significantly different (P < 0.05), PB versus BF.
c
DC-SIGN analysis includes three samples for OspC-1 and three samples for 17-l.